Immunogenicity and safety of primary yellow fever vaccination in patients with rheumatic diseases

Hospital Universitário Cassiano Antônio de Moraes0 个研究点开始时间: 2020年3月5日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•The present study included patients with rheumatic diseases including Rheumatoid Arthritis, Systemic Erythematosus Lupus, Sjögren Syndrome, Systemic Sclerosis and Spondylarthritis over 18 years of age who received yellow fever 17DD anti-mammalian first vaccination in the 2017 Brazilian Campaign from January until December 2017. The control group consisted of individuals who spontaneously searched the Rheumatology Service of HUCAM to receive yellow fever first vacination YF 17DD antimammalian Biomanguinhos-FIOCRUZ in the 2017 Brazilian Campaign and who did not have immune mediated rheumatic disease and no history of previous yellow fever vaccination.

•Exclusion criteria included patients under 18 years of age, patients with history of previous yellow fever vaccination, patients external to HUCAM who have not been referred by a rheumatologist by letter or direct contact of the attending physician indicating the diagnosis and medications in use, those who do not agree to participate; patients immunosuppressed by other causes such as HIV infected, CD4 count less than 200 cells per mm3, organ transplantation history, primary immunodeficiency, neoplasia, previous history of timus disease.

发起方

Hospital Universitário Cassiano Antônio de Moraes